Cargando…

Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial

IMPORTANCE: Agitation is a prevalent, distressing, and burdensome manifestation of Alzheimer dementia in need of an efficacious, safe, and well-tolerated treatment. OBJECTIVE: To confirm the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer dementia. DESIGN,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Daniel, Slomkowski, Mary, Hefting, Nanco, Chen, Dalei, Larsen, Klaus Groes, Kohegyi, Eva, Hobart, Mary, Cummings, Jeffrey L., Grossberg, George T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628834/ https://www.ncbi.nlm.nih.gov/pubmed/37930669 http://dx.doi.org/10.1001/jamaneurol.2023.3810

Ejemplares similares

Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies
por: Marder, Stephen R, et al.
Publicado: (2021)

Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open‐label, long‐term safety and tolerability study
por: Lepola, Ulla, et al.
Publicado: (2018)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
por: Hobart, Mary, et al.
Publicado: (2019)

Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder
por: Clayton, Anita H., et al.
Publicado: (2020)

Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania
por: Vieta, Eduard, et al.
Publicado: (2021)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

M191. EFFECT OF BREXPIPRAZOLE ON ENGAGEMENT IN PATIENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF THREE STUDIES
por: Ismail, Zahinoor, et al.
Publicado: (2020)

Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia
por: Ivkovic, Jelena, et al.
Publicado: (2019)

AGITATION IN ALZHEIMER'S DISEASE: A DECISION TREE FOR HEALTHCARE PROVIDERS
por: Grossberg, George, et al.
Publicado: (2022)

Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale
por: Hobart, Mary, et al.
Publicado: (2018)

A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia
por: Forbes, Andy, et al.
Publicado: (2018)

Impact of agitation in long‐term care residents with dementia in the United States
por: Fillit, Howard, et al.
Publicado: (2021)

Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels
por: Bloniecki, Victor, et al.
Publicado: (2014)

Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study
por: Fleischhacker, W. Wolfgang, et al.
Publicado: (2016)

Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation
por: Ma, Min, et al.
Publicado: (2016)

Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
por: Davies, Simon JC, et al.
Publicado: (2018)

Using electronic health records to estimate the prevalence of agitation in Alzheimer disease/dementia
por: Halpern, Rachel, et al.
Publicado: (2018)

Development of a Claims-Based Algorithm to Identify Patients With Agitation in Alzheimer’s Dementia
por: Hwang, Steve, et al.
Publicado: (2020)

Clinical role of brexpiprazole in depression and schizophrenia
por: Parikh, Nishant B, et al.
Publicado: (2017)

Impressive Response with Brexpiprazole in Ekbom’s syndrome
por: Hsiao, J., et al.
Publicado: (2022)

Agitation near the end of life with dementia: An ethnographic study of care
por: Sampson, Elizabeth L., et al.
Publicado: (2019)

Specific agitation behaviours in dementia differentially contribute to aspects of caregiver burden
por: Patrick, Karlee S., et al.
Publicado: (2022)

Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers
por: Stocker, Hannah, et al.
Publicado: (2023)

Discomfort and agitation in older adults with dementia
por: Pelletier, Isabelle Chantale, et al.
Publicado: (2007)

Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
por: Thomas, Stuart J, et al.
Publicado: (2009)

Ketofol-Dexmedetomidine combination in ECT: A punch for depression and agitation
por: Shams, Tarek, et al.
Publicado: (2014)

Efficacy of Memantine for Agitation in Alzheimer’s Dementia: A Randomised Double-Blind Placebo Controlled Trial
por: Fox, Chris, et al.
Publicado: (2012)

Defining Clinical Trial Estimands: A Practical Guide for Study Teams with Examples Based on a Psychiatric Disorder
por: Polverejan, Elena, et al.
Publicado: (2023)

Gabapentin in the treatment of dementia-associated nocturnal agitation
por: Buskova, Jitka, et al.
Publicado: (2011)

Stress Cardiomyopathy in Association with Severe Agitation in Dementia
por: Amin, Hina, et al.
Publicado: (2019)

ELECTROCONVULSIVE THERAPY FOR AGITATION IN LEWY BODIES DEMENTIA
por: Echeverria, C., et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials
por: Adler, Lenard A., et al.
Publicado: (2022)

Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia
por: Farlow, Martin R., et al.
Publicado: (2013)

Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia
por: Inoue, Yuichi, et al.
Publicado: (2021)

Brexpiprazole—Pharmacologic Properties and Use in Schizophrenia and Mood Disorders
por: Siwek, Marcin, et al.
Publicado: (2023)

Individual music therapy for agitation in dementia: an exploratory randomized controlled trial
por: Ridder, Hanne Mette O., et al.
Publicado: (2013)

Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies
por: Wigal, Sharon B, et al.
Publicado: (2020)

Deuterated dextromethorphan/quinidine for agitation in Alzheimer's disease
por: Khoury, Rita
Publicado: (2021)

Effects of Music on Agitation in Dementia: A Meta-Analysis
por: Pedersen, Siv K. A., et al.
Publicado: (2017)

Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
por: Tampi, Rajesh R, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_esvpksvnldp1uv87hgij0b4dp1